The Clinical and Radiologic Features of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOGAD) in the City of Sakarya, Türkiye
Year: 2025
Type: article
Study design: Observational Study
Abstract: Objective: The study aims to share our knowledge on myelin oligodendrocyte glycoprotein antibody (anti-MOG) seropositivity in patients with demyelinating diseases, focusing on their clinical, serologic, and radiologic characteristics, as well as treatment options for MOG associated disease (MOGAD) cases.Methods: This retrospective study included 332 of 450 demyelinating disease cases, aged 18 to 65 years, who were referred to our clinic from 2017 to 2023 with clinical and/or radiological signs of demyelination, followed by testing for the anti-MOG antibody.We applied the revised 2017 McDonald criteria and the 2023 MOGAD diagnostic criteria to those who tested positive for anti-MOG.Cases of anti-MOG seronegative multiple sclerosis (MS) and non-MOGAD were excluded.We detailed the clinical, serologic, and radiologic characteristics and treatment protocols of anti-MOG-positive/low-positive cases.Results: Among the cases, 16 were clear/low anti-MOG seropositive; of these, 10 were diagnosed with MOGAD, three were MS associated with anti-MOG seropositivity, and three were considered possible MOGAD and followed up.Four MOGAD cases (40%) were double positive for anti-MOG and oligoclonal bands.Three MOGAD cases also had autoimmune diseases.Rare clinical presentations included sixth cranial nerve palsy, tetraparesis secondary to acute disseminated Amaç: Çalışmamız demyelinizan hastalığa sahip olgularımızda miyelin oligodendrosit glikoprotein antikoru (anti-MOG) seropozitifliğini ve MOG ilişkili hastalıklar (MOGAD) tanısı alan olgularımızda klinik, serolojik, radyolojik özellikleri, tedavi seçenekleri hakkındaki deneyimlerimizi paylaşmayı amaçlamaktadır.Yöntemler: Bu retrospektif çalışmaya, 2017-2023 yılları arasında kliniğimize klinik ve/veya radyolojik demiyelinizasyon bulgularıyla sevk edilen, 18-65 yaş aralığındaki 450 demiyelinizan hastalık olgusundan, anti-MOG antikor testi yapılan 332'si dahil edildi.Anti-MOG pozitif olgulara revize edilmiş 2017 McDonald kriterlerini ve 2023 MOGAD tanı kriterlerini uyguladık.Anti-MOG pozitif/düşük pozitif vakaların klinik, serolojik ve radyolojik özelliklerini ve tedavi protokollerini ayrıntılı olarak açıkladık.Anti-MOG seronegatif multipl skleroz (MS) ve non-MOGAD olguları çalışma dışı bırakıldı.Anti-MOG pozitif/düşük pozitif olguların klinik, radyolojik özellikleri ve tedavi protokolleri incelendi.
Source: Gazi Medical Journal
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Award: G4986390751
OpenAlex ID: W4412195324